There are currently 205 clinical trials in Newport Beach, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Hoag Memorial Hospital Presbyterian, USC Norris Oncology/Hematology-Newport Beach, GSK Investigational Site and Eye Research Foundation. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Recruiting
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/15/2024
Locations: Relmada Site, Newport Beach, California
Conditions: Major Depressive Disorder, Depression
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
Recruiting
This is a multi-cohort single arm phase II/screening trial of the combination of a fusion protein that binds EphrinB2 and blocks interaction with cell surface EphB receptors (sEphB4-HSA) in combination with an anti-PD1 antibody (MK-7435 / Pembrolizumab) for treatment of patients with specific solid tumors. There will be four cohorts in this trial: Cohort A, phase II 2nd line trial of sEphB4-HSA and pembrolizumab for platinum refractory metastatic urothelial carcinoma. Cohort B, phase II 3rd lin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: USC Norris Oncology/Hematology - Newport Beach, Newport Beach, California
Conditions: Stage IV Bladder Urothelial Carcinoma, Prostate Cancer, Urothelial Carcinoma
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
Recruiting
The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
02/09/2024
Locations: Research Site 40001-062, Newport Beach, California +1 locations
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
Recruiting
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
02/09/2024
Locations: Research Site 20001-062, Newport Beach, California +1 locations
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Study of AV-1959, an Amyloid Beta Vaccine
Recruiting
Phase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
02/08/2024
Locations: Hoag Memorial Hospital, Newport Beach, California
Conditions: Alzheimer Disease
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
Recruiting
This is a research study to evaluate the safety of an investigational autologous cell product obtained from participant's own adipose tissue as a possible treatment for Alzheimer disease.
Gender:
All
Ages:
Between 45 years and 80 years
Trial Updated:
02/08/2024
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California
Conditions: Alzheimer Disease
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Recruiting
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). This study will also evaluate the long-term safety and tolerabili... Read More
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
02/06/2024
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California
Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: City of Hope Newport Beach, Newport Beach, California
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
Recruiting
Vulvovaginal skin conditions, namely vaginal atrophy, lichen sclerosus, lichen simplex chronicus and lichen planus affecting the female adult population will be treated with a novel gel dressing to test the short- and long-term safety and efficacy of the device.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: WR-PRI, LLC (Newport Beach), Newport Beach, California
Conditions: Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva, Lichen Planus of Vulva, Lichen Simplex of Vulva (Disorder)
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
Recruiting
This is a two-part, open-label phase 1 study to evaluate safety and preliminary efficacy of M-CENK Suspension for Infusion, Cryopreserved, and N-803 for subcutaneous administration in subjects with locally advanced or metastatic solid tumors. The study consists of two cohorts: cohort 1 includes subjects with either newly diagnosed solid tumors who have not received prior therapy or subjects who have received prior first line treatment; and cohort 2 that includes subjects with relapsed/refractory... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
01/19/2024
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California
Conditions: Metastatic Solid Tumor
Empowering Patients' Lung Cancer Screening Uptake
Recruiting
Lung cancer is the leading cause of cancer related mortality. Lung cancer screening (LCS) with low dose computed tomography (LDCT) decreases mortality rate of lung cancer by 20%. Yet many patients who are eligible for lung cancer screening are still falling through the cracks which prevents patients the ability to detect lung cancer early. This study will test the effect of a a multi-level intervention on ordering LDCT within 6 months after patient enrollment. Our proposed intervention includes... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
01/15/2024
Locations: UCI Health - Newport Beach MacArthur, Newport Beach, California
Conditions: Lung Cancer
A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors
Recruiting
To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT) and recommended Phase 2 dose (RP2D) in patients who receive FF-10832 (Gemcitabine Liposome Injection) for treatment of advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Hoag Memorial Hospital Comprehensive Cancer Center, Newport Beach, California
Conditions: Advanced Solid Tumors